Find Locations
For hours, walk-ins and appointments.Special Instructions
State patient's sex on the request form.
Expected Turnaround Time
7 - 11 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum
Volume
1 mL
Minimum Volume
0.1 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube or gel-barrier tube
Collection
Separate serum from cells.
Storage Instructions
Room temperature
Stability Requirements
| Temperature | Period |
|---|---|
| Room temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
| Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Chylous or lipemic serum; hemolysis; gross bacterial contamination. Plasma should be avoided since fibrin may result in the appearance of nonspecific precipitation, which may adversely affect interpretation.
Test Details
Use
This test is intended for measuring human C1q in serum.
Methodology
Radial immunodiffusion (RID)
Reference Interval
See table.
| Age | Male (mg/dL) | Female (mg/dL) |
|---|---|---|
| 0 to 1 y | Not established | Not established |
| 2 to 5 y | 9.8-18.5 | 9.7-19.1 |
| 6 to 17 y | 10.2-19.6 | 10.2-19.4 |
| >17 y | 10.2-20.3 | 10.3-20.5 |
Additional Information
The complement component 1q (or simply C1q) is a protein complex involved in the complement system, which is part of the innate immune system. C1q together with C1r and C1s form the C1 complex.1
Footnotes
1. Coss SL, Zhou D, Chua GT, et al. The complement system and human autoimmune disease. J Autoimmun. 2023 May;137:102979. PubMed 36535812
References
Calatroni M, Moroni G, Conte E, Stella M, Reggiani F, Ponticelli M. Anti-C1q antibodies: a biomarker for diagnosis and management of lupus nephritis. A narrative review. Front Immunol. 2024 June 13;15:1410032. PubMed 38938561
McMurray JC, Schornack BJ, Weskamp AL, et al. Immunodeficiency: Complement disorders. Allergy Asthma Proc. 2024 Sep 1;45(5):305-309. PubMed 39294906
Son M, Diamond B, Santiago-Schwarz F. Fundamental role of C1q in autoimmunity and inflammation. Immunol Res. 2015 Dec;63(1-3)101-106. PubMed 26410546
Thielens NM, Tedesco F, Bohlson SS, Gaboriaud C, Tenner AJ. C1q: A fresh look upon an old molecule. Mol Immunol. 2017 Sep;89:73-83. PubMed 28601358
van de Bovenkamp FS, Dijkstra DJ, van Kooten C, Gelderman KA, Trouw LA. Circulating C1q levels in health and disease, more than just a biomarker. Mol Immunol. 2021 Dec;140:206-216. PubMed 34735869
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf